1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
The refractory gout therapeutics market is undergoing significant transformation, driven by advances in biological drugs, increased patient heterogeneity, and shifting regulatory landscapes. Senior leaders must navigate this evolving environment to seize strategic opportunities and address persistent clinical challenges in the treatment of refractory gout.
Market Snapshot: Refractory Gout Therapeutics
The market for refractory gout therapies demonstrates strong momentum, fueled by a growing need for innovative solutions that extend beyond first-line urate-lowering agents. Strategic investments target populations with suboptimal response to conventional treatments, prompting a surge in next-generation biologics and small molecules. Regional activity underscores variability in adoption and reimbursement, positioning this sector for continued expansion in both established and emerging markets.
Scope & Segmentation
- Mechanism of Action: Uricase agents (non-pegylated and pegylated), uricosuric agents (benzbromarone, lesinurad, probenecid), xanthine oxidase inhibitors (allopurinol, febuxostat, topiroxostat).
- Product Types: Branded products (originator, biosimilar), generics (off-patent).
- Route of Administration: Intravenous (bolus injection, infusion), oral (capsules, tablets), subcutaneous (auto-injector, pre-filled syringe).
- Distribution Channels: Hospital pharmacy (inpatient, outpatient), retail pharmacy (chain, independent), online pharmacy (direct to patient, e-pharmacy), specialty pharmacy (closed network, open network).
- Dosage Forms: Capsules (hard gelatin, HPMC), tablets (film-coated, immediate release), pre-filled syringes (glass, polymer), vials (multi-dose, single-dose).
- Regional Coverage: Americas (United States: California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada; Mexico; Brazil; Argentina), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
- Companies Covered: Takeda Pharmaceutical Company Limited, Horizon Therapeutics plc, AstraZeneca PLC, Ironwood Pharmaceuticals Inc., Amgen Inc., Protalix BioTherapeutics Inc.
Key Takeaways
- Persistent patient heterogeneity is prompting an emphasis on tailored drug strategies, particularly for those who experience limited benefit from traditional urate-lowering agents.
- Biologic and small-molecule candidates are gaining clinical traction among patients with immunogenicity or tolerability challenges, reshaping long-term management approaches.
- Emerging biosimilars and off-patent generics are increasing competition, influencing pricing strategies and driving adoption in cost-sensitive markets.
- Distribution channel innovations, such as expanded specialty pharmacy and online models, are improving drug access and supporting greater adherence.
- Collaborations with digital health partners facilitate enhanced adherence tracking, remote dose titration, and inform ongoing post-market surveillance.
Tariff Impact: U.S. Policy Shifts and Market Effects
Revised United States tariff regulations in 2025 have introduced new pressures on cost structures and access to refractory gout drugs. Higher import duties on both active ingredients and finished biologics have led manufacturers to reassess supply chain strategies, including alternative sourcing and domestic capacity expansion. Payers and providers are leveraging value-based contracts and patient assistance to counterbalance incremental costs, while biosimilars produced regionally accelerate market competition. Regulatory streamlining for domestic products is further shaping competitive and pricing dynamics.
Methodology & Data Sources
Research combines in-depth primary interviews with leading clinicians, pharmacoeconomists, regulatory experts, and patient advocates, as well as comprehensive secondary reviews of peer-reviewed literature, trial data, agency releases, and corporate reports. Analysis incorporates market intelligence databases and regular validation workshops to align findings with real-world practice.
Why This Report Matters
- Enables decision-makers to benchmark emerging refractory gout treatments and anticipate portfolio adjustments.
- Supports planning for shifting tariff impacts and evolving reimbursement models across major global markets.
- Delivers actionable segmentation insights to target investments in regions, mechanisms, and distribution channels.
Conclusion
This analysis provides a strategic foundation for navigating the refractory gout therapeutics landscape’s complexities. Informed by clinical insights and regulatory trends, these findings empower leaders to make data-driven investment and market access decisions.
This product will be delivered within 1-3 business days.
Table of Contents
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emergence of IL-1 inhibitors targeting uncontrolled gout flares in refractory patients
5.2. Development of novel fully human monoclonal antibodies targeting urate crystal deposition in resistant gout
5.3. Advancements in subcutaneous pegloticase formulations to extend half-life and reduce immunogenicity in resistant gout
5.4. Clinical trials assessing safety and efficacy of next-generation oral xanthine oxidase inhibitors in refractory gout sufferers
5.5. Focus on personalized medicine approaches utilizing genetic biomarkers to predict treatment response in treatment-resistant gout
5.6. Strategic collaborations between biotech firms and specialty pharmacies to improve access to pegloticase for severe gout patients
5.7. Emerging research into gene therapy modalities aimed at modifying uric acid regulation pathways in refractory gout cases
5.8. Regulatory landscape evolution facilitating accelerated approval pathways for innovative refractory gout therapeutics
5.9. Real-world evidence studies evaluating long-term safety and sustained urate lowering effects of febuxostat in refractory gout cohorts
5.10. Increasing adoption of digital health solutions for remote monitoring of patient adherence and flare management in chronic refractory gout
5.2. Development of novel fully human monoclonal antibodies targeting urate crystal deposition in resistant gout
5.3. Advancements in subcutaneous pegloticase formulations to extend half-life and reduce immunogenicity in resistant gout
5.4. Clinical trials assessing safety and efficacy of next-generation oral xanthine oxidase inhibitors in refractory gout sufferers
5.5. Focus on personalized medicine approaches utilizing genetic biomarkers to predict treatment response in treatment-resistant gout
5.6. Strategic collaborations between biotech firms and specialty pharmacies to improve access to pegloticase for severe gout patients
5.7. Emerging research into gene therapy modalities aimed at modifying uric acid regulation pathways in refractory gout cases
5.8. Regulatory landscape evolution facilitating accelerated approval pathways for innovative refractory gout therapeutics
5.9. Real-world evidence studies evaluating long-term safety and sustained urate lowering effects of febuxostat in refractory gout cohorts
5.10. Increasing adoption of digital health solutions for remote monitoring of patient adherence and flare management in chronic refractory gout
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
6.2. PESTLE Analysis
8. Drugs for the Treatment of Refractory Gout Market, by Mechanism Of Action
8.1. Introduction
8.2. Uricase Agents
8.2.1. Non-Pegylated Uricase
8.2.2. Pegylated Uricase
8.3. Uricosuric Agents
8.3.1. Benzbromarone
8.3.2. Lesinurad
8.3.3. Probenecid
8.4. Xanthine Oxidase Inhibitors
8.4.1. Allopurinol
8.4.2. Febuxostat
8.4.3. Topiroxostat
8.2. Uricase Agents
8.2.1. Non-Pegylated Uricase
8.2.2. Pegylated Uricase
8.3. Uricosuric Agents
8.3.1. Benzbromarone
8.3.2. Lesinurad
8.3.3. Probenecid
8.4. Xanthine Oxidase Inhibitors
8.4.1. Allopurinol
8.4.2. Febuxostat
8.4.3. Topiroxostat
9. Drugs for the Treatment of Refractory Gout Market, by Product Type
9.1. Introduction
9.2. Branded
9.2.1. Biosimilar
9.2.2. Originator
9.3. Generic
9.3.1. Off-Patent Generic
9.2. Branded
9.2.1. Biosimilar
9.2.2. Originator
9.3. Generic
9.3.1. Off-Patent Generic
10. Drugs for the Treatment of Refractory Gout Market, by Route Of Administration
10.1. Introduction
10.2. Intravenous
10.2.1. Bolus Injection
10.2.2. Infusion
10.3. Oral
10.3.1. Capsules
10.3.2. Tablets
10.4. Subcutaneous
10.4.1. Auto-Injector
10.4.2. Pre-Filled Syringe
10.2. Intravenous
10.2.1. Bolus Injection
10.2.2. Infusion
10.3. Oral
10.3.1. Capsules
10.3.2. Tablets
10.4. Subcutaneous
10.4.1. Auto-Injector
10.4.2. Pre-Filled Syringe
11. Drugs for the Treatment of Refractory Gout Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.2.1. Inpatient
11.2.2. Outpatient
11.3. Online Pharmacy
11.3.1. Direct To Patient
11.3.2. E Pharmacy
11.4. Retail Pharmacy
11.4.1. Chain
11.4.2. Independent
11.5. Specialty Pharmacy
11.5.1. Closed Network
11.5.2. Open Network
11.2. Hospital Pharmacy
11.2.1. Inpatient
11.2.2. Outpatient
11.3. Online Pharmacy
11.3.1. Direct To Patient
11.3.2. E Pharmacy
11.4. Retail Pharmacy
11.4.1. Chain
11.4.2. Independent
11.5. Specialty Pharmacy
11.5.1. Closed Network
11.5.2. Open Network
12. Drugs for the Treatment of Refractory Gout Market, by Dosage Form
12.1. Introduction
12.2. Capsule
12.2.1. Hard Gelatin
12.2.2. Hpmc
12.3. Pre Filled Syringe
12.3.1. Glass
12.3.2. Polymer
12.4. Tablet
12.4.1. Film Coated
12.4.2. Immediate Release
12.5. Vial
12.5.1. Multi Dose
12.5.2. Single Dose
12.2. Capsule
12.2.1. Hard Gelatin
12.2.2. Hpmc
12.3. Pre Filled Syringe
12.3.1. Glass
12.3.2. Polymer
12.4. Tablet
12.4.1. Film Coated
12.4.2. Immediate Release
12.5. Vial
12.5.1. Multi Dose
12.5.2. Single Dose
13. Americas Drugs for the Treatment of Refractory Gout Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Drugs for the Treatment of Refractory Gout Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Drugs for the Treatment of Refractory Gout Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Takeda Pharmaceutical Company Limited
16.3.2. Horizon Therapeutics plc
16.3.3. AstraZeneca PLC
16.3.4. Ironwood Pharmaceuticals, Inc.
16.3.5. Amgen Inc.
16.3.6. Protalix BioTherapeutics, Inc.
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Takeda Pharmaceutical Company Limited
16.3.2. Horizon Therapeutics plc
16.3.3. AstraZeneca PLC
16.3.4. Ironwood Pharmaceuticals, Inc.
16.3.5. Amgen Inc.
16.3.6. Protalix BioTherapeutics, Inc.
List of Figures
FIGURE 1. DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET: RESEARCHAI
FIGURE 26. DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET: RESEARCHSTATISTICS
FIGURE 27. DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET: RESEARCHCONTACTS
FIGURE 28. DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET: RESEARCHARTICLES
FIGURE 2. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET: RESEARCHAI
FIGURE 26. DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET: RESEARCHSTATISTICS
FIGURE 27. DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET: RESEARCHCONTACTS
FIGURE 28. DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY URICASE AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY URICASE AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY NON-PEGYLATED URICASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY NON-PEGYLATED URICASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PEGYLATED URICASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PEGYLATED URICASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY URICASE AGENTS, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY URICASE AGENTS, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY URICOSURIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY URICOSURIC AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BENZBROMARONE, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BENZBROMARONE, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY LESINURAD, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY LESINURAD, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PROBENECID, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PROBENECID, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ALLOPURINOL, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ALLOPURINOL, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY FEBUXOSTAT, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY FEBUXOSTAT, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TOPIROXOSTAT, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TOPIROXOSTAT, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BRANDED, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOSIMILAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOSIMILAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ORIGINATOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ORIGINATOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BRANDED, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY OFF-PATENT GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY OFF-PATENT GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BOLUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BOLUS INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY INFUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY INFUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CAPSULES, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TABLETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AUTO-INJECTOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AUTO-INJECTOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE-FILLED SYRINGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE-FILLED SYRINGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY INPATIENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY INPATIENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY OUTPATIENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DIRECT TO PATIENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DIRECT TO PATIENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY E PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY E PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CHAIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CHAIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY INDEPENDENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY INDEPENDENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLOSED NETWORK, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLOSED NETWORK, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY OPEN NETWORK, BY REGION, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY OPEN NETWORK, BY REGION, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SPECIALTY PHARMACY, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CAPSULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HARD GELATIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HARD GELATIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HPMC, BY REGION, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HPMC, BY REGION, 2025-2030 (USD MILLION)
TABLE 123. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CAPSULE, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CAPSULE, 2025-2030 (USD MILLION)
TABLE 125. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE FILLED SYRINGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 126. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE FILLED SYRINGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 127. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY GLASS, BY REGION, 2018-2024 (USD MILLION)
TABLE 128. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY GLASS, BY REGION, 2025-2030 (USD MILLION)
TABLE 129. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY POLYMER, BY REGION, 2018-2024 (USD MILLION)
TABLE 130. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY POLYMER, BY REGION, 2025-2030 (USD MILLION)
TABLE 131. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE FILLED SYRINGE, 2018-2024 (USD MILLION)
TABLE 132. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE FILLED SYRINGE, 2025-2030 (USD MILLION)
TABLE 133. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 134. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 135. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY FILM COATED, BY REGION, 2018-2024 (USD MILLION)
TABLE 136. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY FILM COATED, BY REGION, 2025-2030 (USD MILLION)
TABLE 137. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 138. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 139. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 140. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 141. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY VIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 142. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY VIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 143. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MULTI DOSE, BY REGION, 2018-2024 (USD MILLION)
TABLE 144. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MULTI DOSE, BY REGION, 2025-2030 (USD MILLION)
TABLE 145. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SINGLE DOSE, BY REGION, 2018-2024 (USD MILLION)
TABLE 146. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SINGLE DOSE, BY REGION, 2025-2030 (USD MILLION)
TABLE 147. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY VIAL, 2018-2024 (USD MILLION)
TABLE 148. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY VIAL, 2025-2030 (USD MILLION)
TABLE 149. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 150. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 151. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY URICASE AGENTS, 2018-2024 (USD MILLION)
TABLE 152. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY URICASE AGENTS, 2025-2030 (USD MILLION)
TABLE 153. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 154. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 155. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 156. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 157. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 158. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 159. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
TABLE 160. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BRANDED, 2025-2030 (USD MILLION)
TABLE 161. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 162. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 163. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 164. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 165. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 166. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 167. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 168. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 169. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 170. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 171. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 172. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 173. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 174. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 175. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 176. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 177. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 178. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 179. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2024 (USD MILLION)
TABLE 180. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SPECIALTY PHARMACY, 2025-2030 (USD MILLION)
TABLE 181. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 182. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 183. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CAPSULE, 2018-2024 (USD MILLION)
TABLE 184. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CAPSULE, 2025-2030 (USD MILLION)
TABLE 185. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE FILLED SYRINGE, 2018-2024 (USD MILLION)
TABLE 186. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE FILLED SYRINGE, 2025-2030 (USD MILLION)
TABLE 187. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 188. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 189. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY VIAL, 2018-2024 (USD MILLION)
TABLE 190. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY VIAL, 2025-2030 (USD MILLION)
TABLE 191. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 192. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 193. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 194. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 195. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY URICASE AGENTS, 2018-2024 (USD MILLION)
TABLE 196. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY URICASE AGENTS, 2025-2030 (USD MILLION)
TABLE 197. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 198. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 199. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 200. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 201. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 202. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 203. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
TABLE 204. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BRANDED, 2025-2030 (USD MILLION)
TABLE 205. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 206. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 207. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 208. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 209. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 210. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 211. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 212. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 213. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 214. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 215. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 216. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 217. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 218. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 219. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 220. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 221. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 222. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 223. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2024 (USD MILLION)
TABLE 224. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SPECIALTY PHARMACY, 2025-2030 (USD MILLION)
TABLE 225. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 226. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 227. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CAPSULE, 2018-2024 (USD MILLION)
TABLE 228. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CAPSULE, 2025-2030 (USD MILLION)
TABLE 229. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE FILLED SYRINGE, 2018-2024 (USD MILLION)
TABLE 230. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE FILLED SYRINGE, 2025-2030 (USD MILLION)
TABLE 231. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 232. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 233. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY VIAL, 2018-2024 (USD MILLION)
TABLE 234. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY VIAL, 2025-2030 (USD MILLION)
TABLE 235. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 236. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 237. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 238. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 239. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY URICASE AGENTS, 2018-2024 (USD MILLION)
TABLE 240. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY URICASE AGENTS, 2025-2030 (USD MILLION)
TABLE 241. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 242. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 243. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 244. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 245. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 246. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 247. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
TABLE 248. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BRANDED, 2025-2030 (USD MILLION)
TABLE 249. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 250. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 251. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 252. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 253. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 254. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 255. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 256. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 257. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 258. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 259. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 260. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 261. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 262. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 263. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 264. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 265. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 266. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 267. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2024 (USD MILLION)
TABLE 268. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SPECIALTY PHARMACY, 2025-2030 (USD MILLION)
TABLE 269. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 270. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 271. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CAPSULE, 2018-2024 (USD MILLION)
TABLE 272. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CAPSULE, 2025-2030 (USD MILLION)
TABLE 273. CANADA DRUGS FOR THE TREATMENT O
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY URICASE AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY URICASE AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY NON-PEGYLATED URICASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY NON-PEGYLATED URICASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PEGYLATED URICASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PEGYLATED URICASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY URICASE AGENTS, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY URICASE AGENTS, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY URICOSURIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY URICOSURIC AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BENZBROMARONE, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BENZBROMARONE, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY LESINURAD, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY LESINURAD, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PROBENECID, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PROBENECID, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ALLOPURINOL, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ALLOPURINOL, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY FEBUXOSTAT, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY FEBUXOSTAT, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TOPIROXOSTAT, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TOPIROXOSTAT, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BRANDED, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOSIMILAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOSIMILAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ORIGINATOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ORIGINATOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BRANDED, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY OFF-PATENT GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY OFF-PATENT GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BOLUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BOLUS INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY INFUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY INFUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CAPSULES, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TABLETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AUTO-INJECTOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AUTO-INJECTOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE-FILLED SYRINGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE-FILLED SYRINGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY INPATIENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY INPATIENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY OUTPATIENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DIRECT TO PATIENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DIRECT TO PATIENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY E PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY E PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CHAIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CHAIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY INDEPENDENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY INDEPENDENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLOSED NETWORK, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLOSED NETWORK, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY OPEN NETWORK, BY REGION, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY OPEN NETWORK, BY REGION, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SPECIALTY PHARMACY, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CAPSULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HARD GELATIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HARD GELATIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HPMC, BY REGION, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HPMC, BY REGION, 2025-2030 (USD MILLION)
TABLE 123. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CAPSULE, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CAPSULE, 2025-2030 (USD MILLION)
TABLE 125. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE FILLED SYRINGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 126. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE FILLED SYRINGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 127. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY GLASS, BY REGION, 2018-2024 (USD MILLION)
TABLE 128. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY GLASS, BY REGION, 2025-2030 (USD MILLION)
TABLE 129. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY POLYMER, BY REGION, 2018-2024 (USD MILLION)
TABLE 130. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY POLYMER, BY REGION, 2025-2030 (USD MILLION)
TABLE 131. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE FILLED SYRINGE, 2018-2024 (USD MILLION)
TABLE 132. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE FILLED SYRINGE, 2025-2030 (USD MILLION)
TABLE 133. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 134. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 135. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY FILM COATED, BY REGION, 2018-2024 (USD MILLION)
TABLE 136. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY FILM COATED, BY REGION, 2025-2030 (USD MILLION)
TABLE 137. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 138. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 139. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 140. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 141. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY VIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 142. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY VIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 143. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MULTI DOSE, BY REGION, 2018-2024 (USD MILLION)
TABLE 144. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MULTI DOSE, BY REGION, 2025-2030 (USD MILLION)
TABLE 145. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SINGLE DOSE, BY REGION, 2018-2024 (USD MILLION)
TABLE 146. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SINGLE DOSE, BY REGION, 2025-2030 (USD MILLION)
TABLE 147. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY VIAL, 2018-2024 (USD MILLION)
TABLE 148. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY VIAL, 2025-2030 (USD MILLION)
TABLE 149. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 150. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 151. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY URICASE AGENTS, 2018-2024 (USD MILLION)
TABLE 152. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY URICASE AGENTS, 2025-2030 (USD MILLION)
TABLE 153. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 154. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 155. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 156. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 157. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 158. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 159. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
TABLE 160. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BRANDED, 2025-2030 (USD MILLION)
TABLE 161. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 162. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 163. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 164. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 165. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 166. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 167. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 168. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 169. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 170. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 171. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 172. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 173. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 174. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 175. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 176. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 177. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 178. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 179. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2024 (USD MILLION)
TABLE 180. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SPECIALTY PHARMACY, 2025-2030 (USD MILLION)
TABLE 181. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 182. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 183. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CAPSULE, 2018-2024 (USD MILLION)
TABLE 184. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CAPSULE, 2025-2030 (USD MILLION)
TABLE 185. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE FILLED SYRINGE, 2018-2024 (USD MILLION)
TABLE 186. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE FILLED SYRINGE, 2025-2030 (USD MILLION)
TABLE 187. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 188. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 189. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY VIAL, 2018-2024 (USD MILLION)
TABLE 190. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY VIAL, 2025-2030 (USD MILLION)
TABLE 191. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 192. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 193. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 194. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 195. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY URICASE AGENTS, 2018-2024 (USD MILLION)
TABLE 196. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY URICASE AGENTS, 2025-2030 (USD MILLION)
TABLE 197. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 198. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 199. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 200. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 201. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 202. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 203. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
TABLE 204. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BRANDED, 2025-2030 (USD MILLION)
TABLE 205. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 206. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 207. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 208. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 209. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 210. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 211. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 212. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 213. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 214. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 215. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 216. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 217. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 218. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 219. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 220. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 221. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 222. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 223. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2024 (USD MILLION)
TABLE 224. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SPECIALTY PHARMACY, 2025-2030 (USD MILLION)
TABLE 225. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 226. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 227. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CAPSULE, 2018-2024 (USD MILLION)
TABLE 228. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CAPSULE, 2025-2030 (USD MILLION)
TABLE 229. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE FILLED SYRINGE, 2018-2024 (USD MILLION)
TABLE 230. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE FILLED SYRINGE, 2025-2030 (USD MILLION)
TABLE 231. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 232. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 233. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY VIAL, 2018-2024 (USD MILLION)
TABLE 234. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY VIAL, 2025-2030 (USD MILLION)
TABLE 235. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 236. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 237. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 238. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 239. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY URICASE AGENTS, 2018-2024 (USD MILLION)
TABLE 240. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY URICASE AGENTS, 2025-2030 (USD MILLION)
TABLE 241. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 242. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 243. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 244. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 245. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 246. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 247. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
TABLE 248. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BRANDED, 2025-2030 (USD MILLION)
TABLE 249. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 250. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 251. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 252. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 253. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 254. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 255. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 256. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 257. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 258. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 259. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 260. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 261. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 262. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 263. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 264. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 265. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 266. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 267. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2024 (USD MILLION)
TABLE 268. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SPECIALTY PHARMACY, 2025-2030 (USD MILLION)
TABLE 269. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 270. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 271. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CAPSULE, 2018-2024 (USD MILLION)
TABLE 272. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CAPSULE, 2025-2030 (USD MILLION)
TABLE 273. CANADA DRUGS FOR THE TREATMENT O
Samples
LOADING...
Companies Mentioned
The companies profiled in this Drugs for the Treatment of Refractory Gout market report include:- Takeda Pharmaceutical Company Limited
- Horizon Therapeutics plc
- AstraZeneca PLC
- Ironwood Pharmaceuticals, Inc.
- Amgen Inc.
- Protalix BioTherapeutics, Inc.
